Liminatus Pharma, Inc. Class A Common Stock
NASDAQ Global SelectTotal Valuation
Liminatus Pharma, Inc. Class A Common Stock carries a market capitalization of 4.17M, placing it among publicly traded companies globally.
| Market Cap | 4.17M |
| Enterprise Value | N/A |
Share Statistics
Liminatus Pharma, Inc. Class A Common Stock currently has 55.97M shares outstanding.
| Shares Outstanding | 55.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1,027.78 |
| P/TBV Ratio | 1,027.78 |
| P/FCF Ratio | -51.60 |
| P/OCF Ratio | -51.60 |
Financial Position
Liminatus Pharma, Inc. Class A Common Stock maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.12 |
| Quick Ratio | 0.99 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -53.76 |
Financial Efficiency
| Return on Equity (ROE) | -8,331.84 |
| Return on Assets (ROA) | -735.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Liminatus Pharma, Inc. Class A Common Stock's stock has declined approximately -94.87025% over the past 52 weeks. The 50-day moving average sits at 4.24, while the 200-day moving average is 12.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.87025% |
| 50-Day Moving Average | 4.24 |
| 200-Day Moving Average | 12.65 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -4.06M, while operating income came in at -4.07M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -4.07M |
| Pretax Income | -12.52M |
| Net Income | -12.52M |
| EBITDA | -4.06M |
| EBIT | -4.07M |
| Earnings Per Share (EPS) | -0.34 |
Balance Sheet
Total book value stands at 300,612.00, with working capital of 352,044.00 providing operational flexibility.
| Cash & Cash Equivalents | 3.02M |
| Total Debt | N/A |
| Net Debt | -1.57M |
| Equity (Book Value) | 300,612.00 |
| Book Value Per Share | 0.01 |
| Working Capital | 352,044.00 |
Cash Flow
Liminatus Pharma, Inc. Class A Common Stock produced -3.97M in operating cash flow over the past twelve months.
| Operating Cash Flow | -3.97M |
| Capital Expenditures | N/A |
| Free Cash Flow | -3.97M |
| FCF Per Share | -0.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.83 |
| FCF Yield | -1.94 |
Stock Splits
Liminatus Pharma, Inc. Class A Common Stock's most recent stock split took place on August 21, 2026 with a 50:1 split ratio.
| Last Split Date | 8/21/2026 |
| Split Ratio | 50:1 |
Scores
Liminatus Pharma, Inc. Class A Common Stock posts an Altman Z-Score of 38.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 38.89 |